Zylox-Tonbridge Medical Technology Co., Ltd. (02190) released its monthly return for the period ended 31 January 2026. The total authorised share capital remained at RMB 344,132,001, comprising 336,350,744 H shares and 7,781,257 Domestic Shares at a par value of RMB 1 each.

The issued H shares totaled 329,504,613 (excluding treasury shares), with 6,846,131 shares held in treasury, leaving no change from the previous month. The publicly listed H shares satisfied the 25% public float requirement as stipulated by the applicable listing rules. Domestic Shares stood at 7,781,257, also unchanged over the reporting period.

In addition, information was provided on an existing share award scheme adopted on 19 December 2024, whereby 861,939 shares are available for issuance or transfer out of treasury under that arrangement. No other share options, warrants, or convertibles were disclosed, and there were no additional movements in the issued or treasury shares during January 2026.